These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 14996765)

  • 21. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol.
    Tollefson GD; Beasley CM; Tamura RN; Tran PV; Potvin JH
    Am J Psychiatry; 1997 Sep; 154(9):1248-54. PubMed ID: 9286184
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial.
    Kahn RS; Fleischhacker WW; Boter H; Davidson M; Vergouwe Y; Keet IP; Gheorghe MD; Rybakowski JK; Galderisi S; Libiger J; Hummer M; Dollfus S; López-Ibor JJ; Hranov LG; Gaebel W; Peuskens J; Lindefors N; Riecher-Rössler A; Grobbee DE;
    Lancet; 2008 Mar; 371(9618):1085-97. PubMed ID: 18374841
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia.
    David SR; Taylor CC; Kinon BJ; Breier A
    Clin Ther; 2000 Sep; 22(9):1085-96. PubMed ID: 11048906
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety of olanzapine.
    Beasley CM; Tollefson GD; Tran PV
    J Clin Psychiatry; 1997; 58 Suppl 10():13-7. PubMed ID: 9265911
    [TBL] [Abstract][Full Text] [Related]  

  • 25. One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia.
    Keefe RS; Young CA; Rock SL; Purdon SE; Gold JM; Breier A;
    Schizophr Res; 2006 Jan; 81(1):1-15. PubMed ID: 16202565
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia.
    Bounthavong M; Okamoto MP
    J Eval Clin Pract; 2007 Jun; 13(3):453-60. PubMed ID: 17518814
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double-blind controlled trial.
    Kennedy JS; Jeste D; Kaiser CJ; Golshan S; Maguire GA; Tollefson G; Sanger T; Bymaster FP; Kinon BJ; Dossenbach M; Gilmore JA; Breier A
    Int J Geriatr Psychiatry; 2003 Nov; 18(11):1013-20. PubMed ID: 14618553
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder.
    Krakowski MI; Czobor P; Citrome L; Bark N; Cooper TB
    Arch Gen Psychiatry; 2006 Jun; 63(6):622-9. PubMed ID: 16754835
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dissociating medication effects from learning and practice effects in a neurocognitive study of schizophrenia: Olanzapine versus haloperidol.
    Boulay LJ; Labelle A; Bourget D; Robertson S; Habib R; Tessier P; Tombaugh T; Milin R
    Cogn Neuropsychiatry; 2007 Jul; 12(4):322-38. PubMed ID: 17558641
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of omega-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol: an open-label pilot study.
    Sivrioglu EY; Kirli S; Sipahioglu D; Gursoy B; Sarandöl E
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1493-9. PubMed ID: 17688987
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia.
    Ascher-Svanum H; Stensland M; Zhao Z; Kinon BJ
    BMC Psychiatry; 2005 Jan; 5():3. PubMed ID: 15649317
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Olanzapine versus haloperidol treatment in first-episode psychosis.
    Sanger TM; Lieberman JA; Tohen M; Grundy S; Beasley C; Tollefson GD
    Am J Psychiatry; 1999 Jan; 156(1):79-87. PubMed ID: 9892301
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Piracetam in the treatment of tardive dyskinesia and akathisia: a case report.
    Fehr C; Dahmen N; Klawe C; Eicke M; Szegedi A
    J Clin Psychopharmacol; 2001 Apr; 21(2):248-9. PubMed ID: 11270931
    [No Abstract]   [Full Text] [Related]  

  • 34. Cost analysis of the treatment of schizophrenia in Thailand: a simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol.
    Kongsakon R; Leelahanaj T; Price N; Birinyi-Strachan L; Davey P
    J Med Assoc Thai; 2005 Sep; 88(9):1267-77. PubMed ID: 16536115
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.
    Tollefson GD; Beasley CM; Tran PV; Street JS; Krueger JA; Tamura RN; Graffeo KA; Thieme ME
    Am J Psychiatry; 1997 Apr; 154(4):457-65. PubMed ID: 9090331
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Olanzapine treatment of residual positive and negative symptoms.
    Buchanan RW; Ball MP; Weiner E; Kirkpatrick B; Gold JM; McMahon RP; Carpenter WT
    Am J Psychiatry; 2005 Jan; 162(1):124-9. PubMed ID: 15625210
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expected incidence of tardive dyskinesia associated with atypical antipsychotics.
    Glazer WM
    J Clin Psychiatry; 2000; 61 Suppl 4():21-6. PubMed ID: 10739327
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison between olanzapine and haloperidol on procedural learning and the relationship with striatal D2 receptor occupancy in schizophrenia.
    Paquet F; Soucy JP; Stip E; Lévesque M; Elie A; Bédard MA
    J Neuropsychiatry Clin Neurosci; 2004; 16(1):47-56. PubMed ID: 14990759
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and tolerability of quetiapine in patients with schizophrenia who switched from haloperidol, olanzapine or risperidone.
    Larmo I; de Nayer A; Windhager E; Lindenbauer B; Rittmannsberger H; Platz T; Jones AM; Altman C;
    Hum Psychopharmacol; 2005 Dec; 20(8):573-81. PubMed ID: 16175656
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antipsychotic drug effects on brain morphology in first-episode psychosis.
    Lieberman JA; Tollefson GD; Charles C; Zipursky R; Sharma T; Kahn RS; Keefe RS; Green AI; Gur RE; McEvoy J; Perkins D; Hamer RM; Gu H; Tohen M;
    Arch Gen Psychiatry; 2005 Apr; 62(4):361-70. PubMed ID: 15809403
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.